Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1980 Apr;17(4):591–594. doi: 10.1128/aac.17.4.591

Treatment of experimental staphylococcal osteomyelitis with rifampin and trimethoprim, alone and in combination.

C W Norden, E Keleti
PMCID: PMC283836  PMID: 7396451

Abstract

Rifampin and trimethoprim were used alone and in combination in the treatment of chronic osteomyelitis due to Staphylococcus aureus in rabbits. Rifampicin levels in infected bone were well above the minimum inhibitory concentration of the infecting strain of S. aureus for at least 4 h after injection. In contrast, trimethoprim levels in diseased bone were below the minimum inhibitory concentration as early as 1 h after injection. Trimethoprim or rifampin, administered alone for 14 days, were ineffective in sterilizing infected rabbit bones. The combination of rifampin plus trimethoprim was significantly more effective (P less than 0.005) than either agents given alone for a comparable duration of time. Staphylococci isolated from the bones of rabbits treated with rifampin alone or rifampin plus trimethoprim were uniformly resistant to rifampin, but retained their susceptibility to trimethoprim.

Full text

PDF
591

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bushby S. R., Hitchings G. H. Trimethoprim, a sulphonamide potentiator. Br J Pharmacol Chemother. 1968 May;33(1):72–90. doi: 10.1111/j.1476-5381.1968.tb00475.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Harvey R. J. Antagonistic interaction of rifampicin and trimethoprim. J Antimicrob Chemother. 1978 Jul;4(4):315–327. doi: 10.1093/jac/4.4.315. [DOI] [PubMed] [Google Scholar]
  3. Interaction between rifampicin and trimethoprim. J Antimicrob Chemother. 1979 Jan;5(1):113–115. doi: 10.1093/jac/5.1.113. [DOI] [PubMed] [Google Scholar]
  4. Norden C. W. Experimental osteomyelitis. I. A description of the model. J Infect Dis. 1970 Nov;122(5):410–418. doi: 10.1093/infdis/122.5.410. [DOI] [PubMed] [Google Scholar]
  5. Norden C. W. Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin. J Infect Dis. 1975 Nov;132(5):493–499. doi: 10.1093/infdis/132.5.493. [DOI] [PubMed] [Google Scholar]
  6. Norden C. W. Experimental osteomyelitis. V. Therapeutic trials with oxacillin and sisomicin alone and in combination. J Infect Dis. 1978 Feb;137(2):155–160. doi: 10.1093/infdis/137.2.155. [DOI] [PubMed] [Google Scholar]
  7. Norden C. W., Keleti E. Experimental osteomyelitis caused by Pseudomonas aeruginosa. J Infect Dis. 1980 Jan;141(1):71–75. doi: 10.1093/infdis/141.1.71. [DOI] [PubMed] [Google Scholar]
  8. Verbist L., Gyselen A. Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am Rev Respir Dis. 1968 Dec;98(6):923–932. doi: 10.1164/arrd.1968.98.6.923. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES